Shilpa Medicare’s 100% subsidiary -- Shilpa Pharma Lifesciences has received certificate of suitability (CEP) from EDQM (European Directorate for the Quality of Medicines & Healthcare) for API, Nifedipine.

Nifedipine is in a class of medications called calcium-channel blockers in the dihydropyridine subclass. Nifedipine is used as an antihypertensive and as an anti-anginal medication. It lowers blood pressure by relaxing the blood vessels so the heart does not have to pump as hard. It controls chest pain by increasing the supply of blood and oxygen to the heart 

The CEP showcases its expertise and commitment to quality-oriented development and commercial production, which meets the expectations of global quality standards.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.